News

Filter

Current filters:

OphthalmicsRoche

1 to 9 of 23 results

Pfenex soars on Lucentis biosimilar deal with Hospira

Pfenex soars on Lucentis biosimilar deal with Hospira

10-02-2015

Shares of US clinical-stage biotech firm Pfenex leapt 28% to $8.85 in morning trading, after the company…

BiosimilarsBiotechnologyGenentechGlobalHospiraLicensingLucentisNovartisOphthalmicsPF582PfenexResearchRoche

FDA approves added indication for Genentech’s Lucentis

FDA approves added indication for Genentech’s Lucentis

08-02-2015

The US Food and Drug Administration on Friday approved Swiss pharma giant Roche subsidiary Genentech’s…

BiotechnologyGenentechLucentisNovartisOphthalmicsRegulationRocheUSA

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

16-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has compared trial data on German…

BayerEyleaGermanyLucentisNovartisOphthalmicsPharmaceuticalPricingRegulationRoche

Generic versions of Valcyte and Activella hit the US market

20-11-2014

Ireland-domiciled pain drugmaker Endo International says that its Qualitest subsidiary has launched a…

ActivellaAmneal PharmaceuticalsEndo InternationalGenericsLopreezaMarkets & MarketingNovo NordiskOphthalmicsRocheUSAValcyteWomen's Health

French regulator requests information from Roche on off-label use of Avastin for wet-AMD

French regulator requests information from Roche on off-label use of Avastin for wet-AMD

07-11-2014

The French pharma regulator, l’Agence nationale de sécurité du médicament et des produits de santé…

AvastinFranceOphthalmicsPharmaceuticalRegulationRoche

Increased scrutiny by EU5 health authorities will encourage off-label use of Avastin for wet-AMD

06-11-2014

Cost-constrained health authorities in the EU5 (France, Germany, Italy, Spain, and the UK) are increasingly…

AvastinBiosimilarsBiotechnologyEuropeFinancialLucentisMarkets & MarketingNovartisOphthalmicsRoche

Eylea beats Avastin and Lucentis for visual acuity in DME patients

Eylea beats Avastin and Lucentis for visual acuity in DME patients

19-10-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer saw their shares leap 8.5% to…

AvastinBayerBiotechnologyEyleaGenentechLucentisNovartisOphthalmicsRegeneron PharmaceuticalsResearchRoche

Cheaper alternative to licensed drug for treating eye disease has similar side-effects, says new Cochrane Review

Cheaper alternative to licensed drug for treating eye disease has similar side-effects, says new Cochrane Review

15-09-2014

Health policies which favor using ranibizumab for treating eye disease in older people over safety concerns…

AvastinbevacizumabBiotechnologyEuropeLucentisNovartisOphthalmicsPricingRanibizumab InjectionRoche

1 to 9 of 23 results

COMPANY SPOTLIGHT

Menarini

Back to top